Merck & Co.’s hangover from the withdrawal of its $2.5 billion a year arthritis drug Vioxx has lifted, according to Chief Executive Richard Clark, and the drugmaker is starting to flex its muscles again.
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/